Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rezvilutamide + androgen deprivation therapy
- Development stage
- Unknown
- Lead developer
- Hengrui Therapeutics
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous, Intramuscular
01
Overview
Rezvilutamide is a second-generation, orally bioavailable androgen receptor (AR) antagonist developed by Jiangsu Hengrui Pharmaceuticals. It is specifically designed with low blood-brain barrier penetration to minimize central nervous system toxicities, such as seizures, which are sometimes associated with other AR inhibitors. In combination with androgen deprivation therapy (ADT), rezvilutamide provides a dual blockade of the androgen signaling axis by reducing circulating testosterone levels and competitively inhibiting the binding of remaining androgens to the AR. This combination was approved in China in June 2022 for the treatment of high-volume metastatic hormone-sensitive prostate cancer (mHSPC) based on the results of the Phase III CHART trial. Fudan University is currently leading a multicenter Phase II trial (MA-PCa-II-023) to evaluate the efficacy of this combination when integrated with radical prostatectomy and metastasis-directed radiotherapy for patients with newly diagnosed oligometastatic hormone-sensitive prostate cancer (OMPC).
- Brand names
- Airuika
- Other names
- rezvilutamide + ADT
02
Targets
AR (Adrenergic receptors)GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on rezvilutamide + androgen deprivation therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rezvilutamide + androgen deprivation therapy.